Vasomotor Symptoms Across the Menopause Transition: Differences Among Women.
Abstract Vasomotor symptoms (VMS) are the primary menopausal symptoms, occurring in up 80% of women and peaking around the final menstrual period. The average duration is 10 years, longer in women with an earlier onset. Compared with non-Hispanic white women, black and Hispanic women are more likely and Asian women are less likely to report VMS. Risk factors include greater body composition (in the early stage of menopausal transition), smoking, anxiety, depression, sensitivity to symptoms, premenstrual syndrome, lower education, and medical treatments, such as hysterectomy, oophorectomy, and breast cancer-re...
Source: Clinical Breast Cancer - November 8, 2018 Category: Cancer & Oncology Authors: Avis NE, Crawford SL, Green R Tags: Obstet Gynecol Clin North Am Source Type: research

Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial.
Abstract Adjuvant endocrine hormonal therapy (EHT) is highly effective and appropriate for nearly all breast cancer patients with hormone receptor-positive tumors, which represent 75% of all breast cancer diagnoses. Long-term use of EHT reduces recurrence rates and nearly halves the risk of death during the second decade after diagnosis. Despite the proven benefits, about 33% of women receiving EHT do not take their medication as prescribed. This causes an increase in the risk for recurrence and death. To promote adherence to EHT among breast cancer patients, this study will develop and pilot-test an intervention ...
Source: Clinical Breast Cancer - November 2, 2018 Category: Cancer & Oncology Authors: Chalela P, Munoz E, Inupakutika D, Kaghyan S, Akopian D, Kaklamani V, Lathrop K, Ramirez A Tags: Contemp Clin Trials Commun Source Type: research

[Bone and calcium metabolism associated with malignancy. Bone and calcium metabolism associated with malignancy.]
Abstract The bones are the most common organ where estrogen-receptor positive breast cancer tends to metastasize. Thus, it is important to treat and prevent bone metastases by studying pathogenesis of developing metastasis to the bones. As advancing treatments have significantly improved the quality of life in patients with bone metastases of breast cancer. Among them, bone-modifying agents have been playing the most crucial roles by reducing the rate of skeletal related events and also having a possibility of favorable effects on prognosis. Zoledronic-acid and denosumab are currently available and denosmab seems ...
Source: Clinical Breast Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Ishikawa T Tags: Clin Calcium Source Type: research

[Bone and calcium metabolism associated with malignancy. Vitamin D and cancer.]
Abstract Vitamin D deficiency and insufficiency are associated with an increased risk of colon cancer. The active form of vitamin D, 1α,25-dihydroxyvitamin D3[1,25(OH)2D3], inhibits proliferation and/or induces differentiation in cells derived from myeloid leukemia, colon cancer, breast cancer, prostate cancer and other malignancies. 1,25(OH)2D3 and its synthetic derivatives activate vitamin D receptor(VDR), a member of the nuclear receptor superfamily, and exhibit antitumor effects by regulating genes involved in cell cycle, differentiation, apoptosis, inflammation and angiogenesis. VDR activation also enha...
Source: Clinical Breast Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Makishima M Tags: Clin Calcium Source Type: research

[Bone and calcium metabolism associated with malignancy. Endocrine therapy of breast cancer.]
Abstract Estrogen receptor(ER)-positive breast cancer accounts for approximately 80%of all breast cancers. The basic concept of endocrine therapy is to deplete estrogen(LH-RH agonist and aromatase inhibitor)and inhibit the action of estrogen against estrogen-dependent growth in ER-positive breast cancer. Recently, new molecular targeting agents, including an mTOR inhibitor and a CDK4/6 inhibitor, have been used in combination with endocrine therapy for the treatment of ER-positive metastatic breast cancer. PMID: 30374008 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Yamashita H Tags: Clin Calcium Source Type: research

[Bone and calcium metabolism associated with malignancy. Clinical Characteristics and Treatment of Cancer Treatment Induced Bone Loss(CTIBL)in Breast Cancer.]
Abstract Breast cancer is a typical hormone-dependent tumor and at the time of diagnosis more than 60% of breast cancers are positive for estrogen receptors and estrogen(E)is required for proliferation. Since breast cancer is a tumor easily to cause micrometastasis, adjuvant hormonal therapy(HT)for 5 to 10 years after surgery that suppresses the action of estrogen actively prevents recurrence is very popular. However, HT with aromatase inhibitor(AI)for postoperative postmenopausal breast cancer markedly reduces the E concentration in the body, leading to significant bone loss and fracture as known as aromatase inh...
Source: Clinical Breast Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Taguchi T Tags: Clin Calcium Source Type: research

CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer.
CONCLUSIONS: CD147 is a putative marker in identifying TNBC or BLBC, and may be useful as a prognosis indicator for patients with TNBC or BLBC post chemotherapy. PMID: 30099407 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 30, 2018 Category: Cancer & Oncology Authors: Liu M, Tsang JYS, Lee M, Ni YB, Chan SK, Cheung SY, Hu J, Hu H, Tse GMK Tags: J Clin Pathol Source Type: research

CDK12: an emerging therapeutic target for cancer.
Abstract Cyclin-dependent kinase 12 (CDK12) belongs to the cyclin-dependent kinase (CDK) family of serine/threonine protein kinases that regulate transcriptional and post-transcriptional processes, thereby modulating multiple cellular functions. Early studies characterised CDK12 as a transcriptional CDK that complexes with cyclin K to mediate gene transcription by phosphorylating RNA polymerase II. CDK12 has been demonstrated to specifically upregulate the expression of genes involved in response to DNA damage, stress and heat shock. More recent studies have implicated CDK12 in regulating mRNA splicing, 3' end pro...
Source: Clinical Breast Cancer - October 30, 2018 Category: Cancer & Oncology Authors: Lui GYL, Grandori C, Kemp CJ Tags: J Clin Pathol Source Type: research

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-na ïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.
Conclusion: Treatment with AAP plus ADT has shown a positive risk-benefit balance and may serve as a new treatment option to improve the prognosis of Japanese mHNPC patients with high-risk features. PMID: 30371895 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 30, 2018 Category: Cancer & Oncology Authors: Fukasawa S, Suzuki H, Kawaguchi K, Noguchi H, Enjo K, Tran N, Todd M, Fizazi K, Matsubara N Tags: Jpn J Clin Oncol Source Type: research

Usefulness of multi-parametric MRI for diagnosis of invasive urothelial cancer: Case reports of bladder and ureteral cancer.
Abstract The presence or absence of metastasis has critical implications for therapeutic decision-making in urothelial cancer (UC). Conventional magnetic resonance imaging (MRI) utilizing anatomic T1- and T2-weighted images has modest efficacy in detecting lymph node and distant metastases in UC. However, incorporation of functional techniques including diffusion weighted imaging and dynamic contrast-enhanced imaging, may improve the accuracy of lesion detection and staging. Multiparametric (mp)MRI is widely used in the imaging of prostate and breast cancers, though its usefulness in UC has yet to be fully elucida...
Source: Clinical Breast Cancer - October 23, 2018 Category: Cancer & Oncology Authors: Hoshi S, Horio K, Numahata K, Hoshi K, Bilim V, Sasagawa I Tags: Mol Clin Oncol Source Type: research

Oncotype testing in patients undergoing intraoperative radiation for breast cancer.
Abstract Oncotype DX recurrence score (RS) predicts risk of distant disease recurrence, and can guide chemotherapy recommendations in hormone positive, human epidermal growth factor 2-negative, early stage breast cancer. The present study aimed to evaluate the pattern of oncotype testing, RS and adjuvant treatment in patients undergoing intraoperative radiotherapy (IORT). Single center prospective data registry was queried for patients receiving IORT between October 2011 and February 2017. Patient demographics, tumor characteristics, RS, systemic therapy and recurrence information were analyzed. A total of 150 wom...
Source: Clinical Breast Cancer - October 23, 2018 Category: Cancer & Oncology Authors: Larson KE, Valente SA, Shah C, Tendulkar RD, Cherian S, Abraham J, Yanda C, Tu C, Echle J, Grobmyer SR Tags: Mol Clin Oncol Source Type: research

Whole-Body Magnetic Resonance Imaging in Oncology: Uses and Indications.
This article reviews the current roles for WB-MRI in the clinical context of limitations of currently used techniques, focusing on bone marrow disease applications. Indication for broader clinical use are discussed, including guideline recommendations. The emerging screening role of WB-MRI in subjects at high risk of cancer is discussed, as is normal population screening. PMID: 30316463 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 16, 2018 Category: Cancer & Oncology Authors: Petralia G, Padhani AR Tags: Magn Reson Imaging Clin N Am Source Type: research

Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer.
Conclusion: On the basis of significant association of p53 over-expression with worse prognostic factors in triple negative breast cancer, therefore we suggest that more large scale studies are needed to validate this finding in loco-regional population. Moreover, high expression of p16 in triple negative breast cancer suggests a potential role of this biomarker in triple negative breast cancer pathogenesis which should be investigated with molecular based research in our population. PMID: 30305801 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 13, 2018 Category: Cancer & Oncology Authors: Ali Hashmi A, Naz S, Hashmi SK, Hussain ZF, Irfan M, Khan EY, Faridi N, Khan A, Edhi MM Tags: BMC Clin Pathol Source Type: research

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis.
In conclusion, the concurrent use of trastuzumab and anthracycline-based NAC for certain HER2-positive locally advanced breast cancers significantly improves the pCR rates without obvious increases in the cardiotoxicity. PMID: 30310287 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 13, 2018 Category: Cancer & Oncology Authors: Wu YT, Xu Z, Zhang K, Wu JS, Li X, Arshad B, Li YC, Wang ZL, Li HY, Wu KN, Kong LQ Tags: Ther Clin Risk Manag Source Type: research

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
CONCLUSIONS: Eight percent of the BRCA1/2 negative patients carry pathogenic variants in other actionable genes. The multigene panel usage improves the diagnostic yield in HBOC testing and it is an effective tool to identify potentially new candidate genes. PMID: 30306255 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 10, 2018 Category: Cancer & Oncology Authors: Bonache S, Esteban I, Moles-Fernández A, Tenés A, Duran-Lozano L, Montalban G, Bach V, Carrasco E, Gadea N, López-Fernández A, Torres-Esquius S, Mancuso F, Caratú G, Vivancos A, Tuset N, Balmaña J, Gutiérrez-Enríquez S, Diez O Tags: J Cancer Res Clin Oncol Source Type: research

HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer.
Abstract Breast cancer had been the first non-hematologic malignancy where sub-types based on molecular characterization had entered clinical practice. HER2 over-expression, due to either gene amplification or protein up-regulation, defines one of these sub-types and is clinically exploited by addition of HER2-targeted treatments to the regimens of treatment. Nevertheless, in many occasions HER2-positive cancers are resistant or become refractory to these therapies. Several mechanisms, such as activation of alternative pathways or loss of expression of the receptor in cancer cells, have been proposed as the cause ...
Source: Clinical Breast Cancer - October 10, 2018 Category: Cancer & Oncology Authors: Voutsadakis IA Tags: Clin Transl Oncol Source Type: research

ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer.
ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. J Clin Invest. 2018 Oct 08;: Authors: Kumar S, Wilkes DW, Samuel N, Blanco MA, Nayak A, Alicea-Torres K, Gluck C, Sinha S, Gabrilovich D, Chakrabarti R Abstract Triple-negative breast cancer (TNBC) is particularly aggressive, with enhanced incidence of tumor relapse, resistance to chemotherapy, and metastases. As the mechanistic basis for this aggressive phenotype is unclear, treatment options are limited. Here, we showed an increased population of myeloid-derived immunosuppressor c...
Source: Clinical Breast Cancer - October 8, 2018 Category: Cancer & Oncology Authors: Kumar S, Wilkes DW, Samuel N, Blanco MA, Nayak A, Alicea-Torres K, Gluck C, Sinha S, Gabrilovich D, Chakrabarti R Tags: J Clin Invest Source Type: research

Number of radiotherapy treatment machines in the population and cancer mortality: an ecological study.
Conclusion: In this ecological study, we found evidence that the population density of RTM is related to cancer mortality independently of other public health parameters. PMID: 30288122 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 6, 2018 Category: Cancer & Oncology Authors: Medenwald D, Vordermark D, Dietzel CT Tags: Clin Epidemiol Source Type: research

Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.
Conclusion: The majority of women diagnosed with bone metastasis from breast cancer initiate a BMA within 1 year of diagnosis, but a large proportion, particularly among the elderly, do not use these therapies. PMID: 30288124 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 6, 2018 Category: Cancer & Oncology Authors: McGrath LJ, Overman RA, Reams D, Cetin K, Liede A, Narod SA, Brookhart MA, Hernandez RK Tags: Clin Epidemiol Source Type: research

Inverse association between estrogen receptor- α DNA methylation and breast composition in adolescent Chilean girls.
CONCLUSIONS: These findings suggest that the methylation profile of ER-α may modulate adolescent response to estrogen and breast composition, which may influence breast cancer risk in adulthood. PMID: 30286806 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 4, 2018 Category: Cancer & Oncology Authors: Binder AM, Stiemsma LT, Keller K, van Otterdijk SD, Mericq V, Pereira A, Santos JL, Shepherd J, Michels KB Tags: Clin Epigenetics Source Type: research

Serum vitamin D decreases during chemotherapy: an Australian prospective cohort study.
This study aims to evaluate variations in serum vitamin D during chemotherapy and the predictive value of latitude, season and pre-existing vitamin D deficiency. METHODS AND STUDY DESIGN: A 12-week prospective cohort study was conducted in chemotherapy-naïve patients in two Australian locations with different sun exposure. Vitamin D deficiency was defined as ≤25 nmol/L and insufficiency 26-50 nmol/L 25(OH) D. Demographics, chemotherapy regimen, nutritional status, sun exposure, geographic location, and sea-son were collected at baseline, 6 and 12 weeks after commencing chemotherapy. RESULTS: Eighty-five p...
Source: Clinical Breast Cancer - October 3, 2018 Category: Cancer & Oncology Authors: Isenring EA, Teleni L, Woodman RJ, Kimlin MG, Walpole E, Karapetis CS, Shawgi S, Kichenadasse G, Marshall S, Koczwara B Tags: Asia Pac J Clin Nutr Source Type: research

Non-participation in breast cancer screening among previous cancer patients.
CONCLUSION: Screening for breast cancer may help diagnose breast cancer at an early stage. Women with previous cancer who are not undergoing current treatment or in palliative care have the same propensity to participate as other women invited to breast cancer screening. Women with previous gynaecological cancer were less likely to participate in breast cancer screening than women with other cancer types. These results may only be generalised to similar health care systems. PMID: 30097713 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 1, 2018 Category: Cancer & Oncology Authors: Virgilsen LF, Pedersen AF, Andersen B, Vedsted P Tags: J Cancer Res Clin Oncol Source Type: research

Efficacy of Huaier granule in patients with breast cancer.
In this study, we aimed to evaluate the efficacy of Huaier granule in breast cancer patients. METHODS: Our study included 284 breast cancer patients treated with or without Huaier granule between January 2005 and October 2016 at Qilu Hospital, Shandong University, Jinan, China. Retrospective data obtained included demographics, clinicopathological characteristics, disease-free survival (DFS), serum concentrations of tumor markers, the Karnofsky performance scale (KPS), and incidences of emotional symptoms. DFS was the main outcome measure. RESULTS: Of the patients included, 144 were classified into the control gr...
Source: Clinical Breast Cancer - October 1, 2018 Category: Cancer & Oncology Authors: Zhang Y, Wang X, Chen T Tags: Clin Transl Oncol Source Type: research

Corrigendum.
Authors: PMID: 30266382 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 30, 2018 Category: Cancer & Oncology Tags: Clin Breast Cancer Source Type: research

Cancer-related coping processes as predictors of depressive symptoms, trajectories, and episodes.
CONCLUSIONS: Greater engagement in cancer-related avoidant coping was associated with all three indicators of depression, and greater approach-oriented coping was related to more favorable outcomes (except MDE). Sustained or increasing coping through emotional expression or acceptance predicted recovery from initially high depressive symptoms. Approach- and avoidance-oriented coping processes constitute malleable targets for preventive and ameliorative approaches. (PsycINFO Database Record (c) 2018 APA, all rights reserved). PMID: 30265041 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 29, 2018 Category: Cancer & Oncology Authors: Stanton AL, Wiley JF, Krull JL, Crespi CM, Weihs KL Tags: J Consult Clin Psychol Source Type: research

Diagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients.
This study explored the value of measuring programmed death 1 (PD-1) in peripheral blood, combined with breast ultrasound using the Breast Imaging Reporting and Data System (BI-RADS) classification, for differentiation between benign and malignant breast tumors. Materials and methods: We enrolled 113 patients with breast cancer and 66 patients with benign breast tumors who were admitted to Hangzhou First People's Hospital from September 2014 to August 2017. The mRNA level of PD-1 was detected by quantitative real-time polymerase chain reaction. Results: The mRNA levels of PD-1 were significantly higher in the per...
Source: Clinical Breast Cancer - September 16, 2018 Category: Cancer & Oncology Authors: Fang J, Shao Y, Su J, Wan Y, Bao L, Wang W, Kong F Tags: Ther Clin Risk Manag Source Type: research

Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030.
Conclusion: In the aging population of Hungary, cancer incidence will increase considerably over previous projections. Although a large portion of the most rapidly rising cancers are avoidable by implementing public health programs, a substantial portion remains inevitably incurable. PMID: 30214314 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 16, 2018 Category: Cancer & Oncology Authors: Menyhárt O, Fekete JT, Győrffy B Tags: Clin Epidemiol Source Type: research

Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray.
Abstract Molecular phenotyping and tissue microarray (TMA) studies have identified distinct invasive breast carcinoma subtypes: Luminal A, luminal B, enriched with overexpressed human epidermal growth factor receptor 2 (HER-2) and triple-negative, i.e., negative for HER-2, as well as for estrogen and progesterone receptor (ER and PR, respectively) expression. These subtypes are useful in clinical management, since they bear distinct prognoses and predictive responses to targeted therapy. However, although molecular profiling provides important prognostic indicators, breast cancer risk stratification remains a chal...
Source: Clinical Breast Cancer - September 16, 2018 Category: Cancer & Oncology Authors: Logullo AF, Pasini FS, Nonogaki S, Rocha RM, Soares FA, Brentani MM Tags: Mol Clin Oncol Source Type: research

Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer.
CONCLUSIONS: EMP2 is superior to EpCAM for capturing both MCF7 and MDA-MB-231 cells. Additionally, EMP2 is a novel biomarker and capable of capturing breast cancer cells in patient blood samples. PMID: 30218306 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Chen Q, Yao L, Burner D, Minev B, Lu L, Wang M, Ma W Tags: Clin Transl Oncol Source Type: research

Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.
CONCLUSIONS: This study provides an evidence for polymorphism of CYP3A4 gene associated with the development of breast cancer, also a new insight into etiology of breast cancer. However, the underlying mechanism of the CYP3A4 gene in breast cancer is necessary for further study. PMID: 30218411 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Liu X, Huang X, Zhang S, Niu F, Ouyang Y, Shou Z, Liu J Tags: Int J Clin Oncol Source Type: research

Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City.
Abstract BACKGROUND: Cardiovascular disease (CVD) and cancer are major causes of death in Japan. As most CVDs are chronic and often aggravate, long-term follow-up is necessary. Although some cancer patients and survivors have CVD, its prognostic significance and prevalence are unknown. Therefore, we conducted a retrospective study at our center to determine the prevalence of cancer patients with CVD. METHODS: In 2015, our 10-year (2005-2014) cancer registry was summarized. Comorbidities including left ventricular dysfunction, atrial fibrillation (AF), ischemic heart disease, aortic stenosis, venous thromboemb...
Source: Clinical Breast Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Okura Y, Takayama T, Ozaki K, Tanaka H, Seki H, Takenouchi T, Sato N, Minamino T Tags: Int J Clin Oncol Source Type: research

Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017.
Abstract Race, ethnicity, sex, and age are demographic factors that can influence drug exposure and/or response, and can consequently affect treatment outcome. We evaluated demographic subgroup enrollment patterns in new therapeutic products approved by the US Food and Drug Administration (FDA) for the treatment of select cancers-breast, colorectal, lung, and prostate-that have comparative differences in morbidity and/or mortality among some demographic subgroups. In submissions of products approved between 2008 and 2013, participants (n = 22,481) were white (80%), from outside the United States (74%), between 17 ...
Source: Clinical Breast Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Ramamoorthy A, Knepper TC, Merenda C, Mendoza M, McLeod HL, Bull J, Zhang L, Pacanowski M Tags: Clin Pharmacol Ther Source Type: research

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.
Conclusion Recommendations for appropriate end points for metastatic breast cancer clinical trials focus on biologic subtype and line of therapy and the magnitude of absolute and relative gains that would represent meaningful clinical benefit. PMID: 30212295 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 13, 2018 Category: Cancer & Oncology Authors: Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA Tags: J Clin Oncol Source Type: research

Assessment of local tissue water in the arms and trunk of breast cancer survivors with and without upper extremity lymphoedema.
Abstract Given the paucity of information on local tissue water (LTW) in the upper extremity and trunk of women after breast cancer surgery, the purpose of this study was to compare tissue dielectric constant (TDC) values between the affected and unaffected sides of breast cancer survivors with and without upper extremity lymphoedema (LE). Differences in LTW were assessed using the TDC method for three sites in the upper limbs, three sites in the lateral thorax and two sites on the back. Additional measures included demographic and clinical characteristics, arm circumference and bioimpedance analysis. For the 112 ...
Source: Clinical Breast Cancer - September 12, 2018 Category: Cancer & Oncology Authors: Mazor M, Smoot BJ, Mastick J, Mausisa G, Paul SM, Kober KM, Elboim C, Singh K, Conley YP, Mickevicius G, Field J, Hutchison H, Miaskowski C Tags: Clin Physiol Funct Imaging Source Type: research

ColX α1 is a Stromal Component that Colocalizes with Elastin in the Breast Tumor Extracellular Matrix.
ColXα1 is a Stromal Component that Colocalizes with Elastin in the Breast Tumor Extracellular Matrix. J Pathol Clin Res. 2018 Sep 12;: Authors: Wang Y, Lu S, Xiong J, Singh K, Hui Y, Zhao C, Brodsky AS, Yang D, Jolly G, Ouseph M, Schorl C, DeLellis RA, Resnick MB Abstract The tumor microenvironment regulates tissue development and homeostasis, and its dysregulation contributes to neoplastic progression. Increased expression of type X collagen α-1 (ColXα1) in tumor-associated stroma correlates with poor pathologic response to neoadjuvant chemotherapy in estrogen receptor (ER) and huma...
Source: Clinical Breast Cancer - September 12, 2018 Category: Cancer & Oncology Authors: Wang Y, Lu S, Xiong J, Singh K, Hui Y, Zhao C, Brodsky AS, Yang D, Jolly G, Ouseph M, Schorl C, DeLellis RA, Resnick MB Tags: J Pathol Clin Res Source Type: research

HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk.
Abstract Breast cancer (BrCa) is the malignant tumor that most seriously threatens female health; however, the molecular mechanism underlying its progression remains unclear. Here, we found that conditional deletion of HIC1 in the mouse mammary gland might contribute to premalignant transformation in the early stage of tumor formation. Moreover, the chemokine CXCL14 secreted by HIC1-deleted BrCa cells bound to its novel cognate receptor GPR85 on mammary fibroblasts in the microenvironment and was responsible for activating these fibroblasts via the ERK1/2, Akt, and neddylation pathways, whereas the activated fibro...
Source: Clinical Breast Cancer - September 11, 2018 Category: Cancer & Oncology Authors: Wang Y, Weng X, Wang L, Hao M, Li Y, Hou L, Liang Y, Wu T, Yao M, Lin G, Jiang Y, Fu G, Hou Z, Meng X, Lu J, Wang J Tags: J Clin Invest Source Type: research

Progress in adjuvant systemic therapy for breast cancer.
art M Abstract The prognosis of patients with early stage breast cancer has greatly improved in the past three decades. Following the first adjuvant endocrine therapy and chemotherapy trials, continuous improvements of clinical outcomes have been achieved through intense therapeutic escalation, albeit with increased health-care costs and treatment-related toxicities. In contrast to the advances achieved in surgery or radiotherapy, the identification of the patient subgroups that will derive clinical benefit from therapeutic escalation has proved to be a daunting process hindered by a lack of collaboration between ...
Source: Clinical Breast Cancer - September 11, 2018 Category: Cancer & Oncology Authors: Pondé NF, Zardavas D, Piccart M Tags: Nat Rev Clin Oncol Source Type: research

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
AI Abstract Most HER2-positive metastatic breast cancer patients continue to relapse. Incomplete access to all target HER2-positive cells in metastases and tumor tissues is a potential mechanism of resistance to trastuzumab. The location of locally bound trastuzumab was evaluated in HER2-positive tissues in vivo and as in vivo xenografts or metastases models in mice. Microenvironmental elements of tumors were related to bound trastuzumab using immunohistochemical staining and include tight junctions, vasculature, vascular maturity, vessel patency, hypoxia and HER2 to look for correlations. Trastuzumab was evaluat...
Source: Clinical Breast Cancer - September 8, 2018 Category: Cancer & Oncology Authors: Baker JHE, Kyle AH, Reinsberg SA, Moosvi F, Patrick HM, Cran J, Saatchi K, Häfeli U, Minchinton AI Tags: Clin Exp Metastasis Source Type: research

Information-seeking, information sources and ongoing support needs after discharge to prevent cancer-related lymphoedema.
Conclusions: Both gynaecological and breast cancer patients reported ongoing care needs, but that details of information-seeking behaviours differed. PMID: 30192947 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 6, 2018 Category: Cancer & Oncology Authors: Tsuchiya M, Masujima M, Mori M, Takahashi M, Kato T, Ikeda SI, Shimizu C, Kinoshita T, Shiino S, Suzuki M Tags: Jpn J Clin Oncol Source Type: research

The potential of exosomes derived from colorectal cancer as a biomarker.
Abstract Colorectal cancer (CRC) is one of the most frequent causes of cancer death. The diagnosis and treatment for metastatic CRC and patients with drug resistance remains poor. Cancer cells characteristically produce and release exosomes, which act as a new signal pattern in the occurrence and development of tumors. Circulating exosomes constitute promising biomarkers for early diagnosis of cancer patients. However, the potential of exosomes for clinical biomarker is hampered by their variousness and multi-sources. To this aim, we set out to solve the problem of discrimination and classification of exosomes. Th...
Source: Clinical Breast Cancer - September 5, 2018 Category: Cancer & Oncology Authors: Xiao Y, Li Y, Yuan Y, Liu B, Pan S, Liu Q, Qi X, Zhou H, Dong W, Jia L Tags: Clin Chim Acta Source Type: research

Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
We present the case of a postmenopausal patient with a secondary metastatic ER-positive, HER2-negative breast cancer who was successfully treated with fulvestrant and alpelisib following six lines of therapy. The tumour showed two uncommon PIK3CA mutations, and with the combination of alpelisib and fulvestrant the patient went from ECOG grade 3, before the start of this therapy, to ECOG grade 1 during treatment until progressive disease after 6 months. This unexpected benefit emphasizes the importance of performing a Next Generation Sequencing (NGS)-based assay to screen for several cancer genes in the metastatic sett...
Source: Clinical Breast Cancer - September 5, 2018 Category: Cancer & Oncology Authors: Hoste G, Slembrouck L, Jongen L, Punie K, Matton T, Vander Borght S, Vanden Bempt I, Menten J, Wildiers H, Floris G, Arteaga C, Neven P Tags: Clin Drug Investig Source Type: research

Managing cancer risk in patients with systemic lupus erythematous.
Abstract INTRODUCTION: Numerous studies have clearly demonstrated that there is an altered cancer risk profile in patients with systemic lupus erythematous (SLE) versus the general population. This includes a higher risk of certain cancers (e.g. hematologic, lung) and a decreased risk of others (e.g. breast cancer). Several determinants could be behind this altered risk; these include immunosuppressant drugs, viral exposures, genetic factors, and other variables. Area covered: We review what is known regarding specific risk profiles and risk factors for some key cancers in SLE, including hematologic malignancies a...
Source: Clinical Breast Cancer - September 5, 2018 Category: Cancer & Oncology Authors: Ladouceur A, Bernatsky S, Ramsey-Goldman R, Clarke AE Tags: Expert Rev Clin Immunol Source Type: research

Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis.
We report here that the ubiquitin-specific protease USP7 was physically associated with the MRN-MDC1 complex and that the MRN-MDC1 complex acted as a platform for USP7 to efficiently deubiquitinate and stabilize MDC1, thereby sustaining the DDR. Accordingly, depletion of USP7 impaired the engagement of the MRN-MDC1 complex and the consequent recruitment of the downstream factors p53-binding protein 1 (53BP1) and breast cancer protein 1 (BRCA1) at DNA lesions. Significantly, USP7 was overexpressed in cervical cancer, and the level of its expression positively correlated with that of MDC1 and worse survival rates for patient...
Source: Clinical Breast Cancer - September 4, 2018 Category: Cancer & Oncology Authors: Su D, Ma S, Shan L, Wang Y, Wang Y, Cao C, Liu B, Yang C, Wang L, Tian S, Ding X, Liu X, Yu N, Song N, Liu L, Yang S, Zhang Q, Yang F, Zhang K, Shi L Tags: J Clin Invest Source Type: research

Limitations in the Effect of Screening on Breast Cancer Mortality.
Conclusion Screening had a clear long-term beneficial effect with a 20% reduction in breast cancer-associated mortality in the invited population. However, this effect was, by nature, restricted to breast cancer deaths in women who could potentially benefit from screening. Our study highlights the complexity in evaluating the long-term effect of breast cancer screening from observational data. PMID: 30179570 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 4, 2018 Category: Cancer & Oncology Authors: Beau AB, Andersen PK, Vejborg I, Lynge E Tags: J Clin Oncol Source Type: research

Long noncoding RNA MIR31HG inhibits hepatocellular carcinoma proliferation and metastasis by sponging microRNA-575 to modulate ST7L expression.
CONCLUSIONS: Overall, our study illuminates the role of MIR31HG as a miRNA sponge in HCC, and sheds new light on lncRNA-directed diagnostics and therapeutics in HCC. PMID: 30176933 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 3, 2018 Category: Cancer & Oncology Authors: Yan S, Tang Z, Chen K, Liu Y, Yu G, Chen Q, Dang H, Chen F, Ling J, Zhu L, Huang A, Tang H Tags: J Exp Clin Cancer Res Source Type: research

Cytokines, breast cancer stem cells (BCSCs) and chemoresistance.
Abstract Chemotherapy resistance of breast cancer poses a great challenge to the survival of patients. During breast cancer treatment, the development of intrinsic and acquired drug resistance tends to further induce adverse prognosis, such as metastasis. In recent years, the progress of research on cytokine-modulated tumor microenvironment and breast cancer stem cells (BCSCs) has shed light on defining the mechanisms of drug resistance gradually. In this review, we have discussed cytokine regulation on breast cancer chemoresistance. Cytokines can affect tumor cell behavior or reprogram tumor niche through specifi...
Source: Clinical Breast Cancer - September 3, 2018 Category: Cancer & Oncology Authors: Chen W, Qin Y, Liu S Tags: Clin Transl Med Source Type: research

ESR1-promoter-methylation status in primary breast cancer and its corresponding metastases.
Abstract The role of ESR1 methylation in breast cancer and its influence on disease progression is not yet fully understood. Healthy breast tissue usually does not show ESR1 promoter methylation, whereas the frequency of ESR1 methylation appears to increase in primary breast cancer and in metastatic disease. Although women with ER positive breast cancer have a good prognosis, some will relapse. We aimed to evaluate the methylation status of ESR1 in primary breast cancer and its corresponding metastases by a methylation-specific real-time PCR and to correlate the methylation status with clinical outcome. Women who ...
Source: Clinical Breast Cancer - September 1, 2018 Category: Cancer & Oncology Authors: Kirn V, Strake L, Thangarajah F, Richters L, Eischeid H, Koitzsch U, Odenthal M, Fries J Tags: Clin Exp Metastasis Source Type: research

5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability.
Abstract Symptoms of depression are present in over half of all cancer patients, and selective serotonin reuptake inhibitor (SSRI) anti-depressant medications are prescribed to nearly a quarter of these individuals in order to cope with their disease. Previous studies have provided evidence that elevated serotonin (5-HT) and serotonin receptor levels may contribute to oncogenic progression, yet little is known regarding the mechanism by which this occurs. The data demonstrated that serotonin receptor mRNAs and proteins are expressed across diverse cancer types, and that serotonin stimulation of tumor cells activat...
Source: Clinical Breast Cancer - August 30, 2018 Category: Cancer & Oncology Authors: Ballou Y, Rivas A, Belmont A, Patel L, Amaya CN, Lipson S, Khayou T, Dickerson EB, Nahleh Z, Bryan BA Tags: Mol Clin Oncol Source Type: research

Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.
ura M Abstract Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC), which was previously treated with non-steroidal aromatase inhibitors (NSAI). Data from unselected populations may be useful for defining the optimal therapeutic algorithm within a clinical setting. Data from 264 HR+, HER2-MBC patients who received Exe-Eve treatment in combination, following the failure of NSAIs was retrospectively analyzed. Different lines o...
Source: Clinical Breast Cancer - August 30, 2018 Category: Cancer & Oncology Authors: Riccardi F, Colantuoni G, Diana A, Mocerino C, Cartenì G, Lauria R, Febbraro A, Nuzzo F, Addeo R, Marano O, Incoronato P, De Placido S, Ciardiello F, Orditura M Tags: Mol Clin Oncol Source Type: research

Abscopal effect following radiation monotherapy in breast cancer: A case report.
Abstract Radiotherapy has been found to be valuable for the control and eradication of local foci in various malignant tumors. The abscopal effect is determined as a systemic antitumor response at a distance from the irradiation site invoked by local irradiation. We herein present an extremely rare case of breast cancer in a 64-year-old woman, in whom the abscopal effect was observed after radiotherapy induced an antitumor response in all metastatic lesions, without any combination therapy. The patient was admitted to our hospital complaining of a breast mass and pain at the left hip, and was diagnosed with breast...
Source: Clinical Breast Cancer - August 30, 2018 Category: Cancer & Oncology Authors: Azami A, Suzuki N, Azami Y, Seto I, Sato A, Takano Y, Abe T, Teranishi Y, Tachibana K, Ohtake T Tags: Mol Clin Oncol Source Type: research